Roche announced the M&A of Brisbane, California biotech company InterMune, Inc. for a cash transaction totaling $8.3 billion.
Based on a price of $74.00 per share, the M&A has been approved by the boards of both companies.
InterMune focuses on developing and commercializing therapies in pulmonology and orphan fibrotic diseases.
The M&A of InterMune would strength Roche’s portfolio of respiratory drugs.
Under the M&A deal, Roche will start a tender offer non later than August 29, 2014 and InterMune will file a statement of recommendation to shareholders.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Report : Partnering Agreements with Roche 2009-2014
Report: Pharma and Biotech M&A Trends 2009-2014
View: Current Partnering’s M&A Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Partnering activity – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Parnering activity – latest trends in big biotech deal making activity